BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22968966)

  • 1. Detection of cytoplasmic nucleophosmin expression by imaging flow cytometry.
    Grimwade L; Gudgin E; Bloxham D; Bottley G; Vassiliou G; Huntly B; Scott MA; Erber WN
    Cytometry A; 2012 Oct; 81(10):896-900. PubMed ID: 22968966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A surrogate marker to detect nucleophosnim (NPM1) gene mutations in the cytoplasm of acute myeloid leukemia (AML) blast cells in 30 adult Iraqi patients.
    Al-Husseinawi EK
    Ann Saudi Med; 2013; 33(6):539-46. PubMed ID: 24413856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.
    Konoplev S; Huang X; Drabkin HA; Koeppen H; Jones D; Kantarjian HM; Garcia-Manero G; Chen W; Medeiros LJ; Bueso-Ramos CE
    Cancer; 2009 Oct; 115(20):4737-44. PubMed ID: 19637342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia.
    Dai Q; Ren Y
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):205-11. PubMed ID: 23591014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?
    Mattsson G; Turner SH; Cordell J; Ferguson DJ; Schuh A; Grimwade LF; Bench AJ; Weinberg OK; Marafioti T; George TI; Arber DA; Erber WN; Mason DY
    Haematologica; 2010 Apr; 95(4):670-3. PubMed ID: 20015883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PML protein analysis using imaging flow cytometry.
    Grimwade L; Gudgin E; Bloxham D; Scott MA; Erber WN
    J Clin Pathol; 2011 May; 64(5):447-50. PubMed ID: 21177751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.
    Du Pisani LA; Shires K
    Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):106-14. PubMed ID: 26183674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
    Sorigue M; Espasa A; Zamora L; Junca J
    Ann Hematol; 2020 May; 99(5):1135-1136. PubMed ID: 32170360
    [No Abstract]   [Full Text] [Related]  

  • 9. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
    Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
    Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
    Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
    Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
    Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
    Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mutations of the nucleophosmin (NPM-1) gene in Egyptian patients with acute myeloid leukemia: a pilot study.
    Kassem N; Hamid AA; Attia T; Baathallah S; Mahmoud S; Moemen E; Safwat E; Khalaf M; Shaker O
    J Egypt Natl Canc Inst; 2011 Jun; 23(2):73-8. PubMed ID: 22099964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.
    Salipante SJ; Fromm JR; Shendure J; Wood BL; Wu D
    Mod Pathol; 2014 Nov; 27(11):1438-46. PubMed ID: 24743218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometry in detection of Nucleophosmin 1 mutation in acute myeloid leukemia patients: A reproducible tertiary hospital experience.
    El-Gamal RAE; Hashem AE; Habashy DM; Abou Elwafa MAZ; Boshnak NH
    Int J Lab Hematol; 2021 Feb; 43(1):68-75. PubMed ID: 32856429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
    Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
    Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia.
    Oelschlaegel U; Koch S; Mohr B; Schaich M; Falini B; Ehninger G; Thiede C
    Leukemia; 2010 Oct; 24(10):1813-6. PubMed ID: 20724983
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
    Falini B; Martelli MP; Bolli N; Bonasso R; Ghia E; Pallotta MT; Diverio D; Nicoletti I; Pacini R; Tabarrini A; Galletti BV; Mannucci R; Roti G; Rosati R; Specchia G; Liso A; Tiacci E; Alcalay M; Luzi L; Volorio S; Bernard L; Guarini A; Amadori S; Mandelli F; Pane F; Lo-Coco F; Saglio G; Pelicci PG; Martelli MF; Mecucci C
    Blood; 2006 Sep; 108(6):1999-2005. PubMed ID: 16720834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
    Falini B; Nicoletti I; Bolli N; Martelli MP; Liso A; Gorello P; Mandelli F; Mecucci C; Martelli MF
    Haematologica; 2007 Apr; 92(4):519-32. PubMed ID: 17488663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.